-
PSPro Enables High-Resolution Spatial Proteomics in Tissue S
2026-06-03
Mao et al. introduce PSPro, a proximity labeling-based approach for spatial proteome profiling with single-cell-type resolution in complex tissue slices. This innovation enables unbiased, high-coverage proteomic mapping of multiple cell types within a single experiment, offering new insights into tissue heterogeneity and microenvironmental organization.
-
iPSC-Based Drug Screening for Ultrarare Disease Clinical Tri
2026-06-03
This study introduces a patient-derived iPSC platform to prescreen therapeutics for ultrarare metabolic disorders, addressing the high uncertainty in trial selection for novel mutations. The approach enabled personalized drug efficacy evaluation, guiding safer and more effective clinical trial enrollment.
-
Decitabine in Epigenetic Autoimmunity: Beyond Cancer Researc
2026-06-02
Explore the multifaceted role of Decitabine (5-Aza-2'-deoxycytidine) in modulating DNA methylation for cancer and autoimmune disease research. This article uniquely bridges tumor suppressor gene reactivation with emerging insights from autoimmune epigenetics, providing researchers with advanced perspectives and practical guidance.
-
Hypoxia and Immunometabolism in Tumor Microenvironments
2026-06-02
This review elucidates how hypoxia-driven metabolic reprogramming shapes the immunosuppressive tumor microenvironment, focusing on the interplay between glucose metabolism and immune cell function. The findings highlight the central role of altered D-glucose utilization in tumor progression and point toward new therapeutic strategies targeting metabolic pathways.
-
Foxp1 Suppresses EndMT and Valvular Calcification in CKD Mod
2026-06-01
This study demonstrates that endothelial-specific overexpression of Foxp1 inhibits the endothelial-to-mesenchymal transition (EndMT) and attenuates valvular calcification (VC) in chronic kidney disease (CKD) by suppressing Notch pathway activation. These findings reveal regulatory nodes in the Jagged-1/Notch axis that may be targeted to reduce cardiovascular risk in CKD.
-
BMP4-GPX4 Axis Reduces Ferroptosis in Glaucoma Stem Cell Mod
2026-06-01
This study demonstrates that BMP4-GPX4 pathway activation mitigates ferroptosis and supports the differentiation of retinal stem cells (RSCs) into retinal ganglion cells (RGCs) after transplantation in a high intraocular pressure (IOP) glaucoma mouse model. The findings offer a mechanistic advance in neuroprotection and stem cell therapy, with translational implications for glaucoma treatment.
-
2-Hydroxypropyl-β-cyclodextrin: Technical Use and Protocols
2026-05-31
2-Hydroxypropyl-β-cyclodextrin addresses the recurring challenge of solubilizing poorly water-soluble, hydrophobic compounds—especially those with aromatic or phenyl groups—by forming inclusion complexes that improve aqueous solubility. It is validated for use as a drug formulation excipient or for pharmaceutical solubility improvement workflows. Applications outside these defined contexts, such as alternative delivery or non-solubility roles, are not supported by current product documentation.
-
Moxidectin (SKU B3611): Reliable Macrocyclic Lactone Anthelm
2026-05-30
This article explores how Moxidectin (SKU B3611), a macrocyclic lactone anthelmintic, addresses critical laboratory challenges in antifungal synergy and cell-based assays. Through scenario-driven Q&A, we detail evidence-based workflows, protocol parameters, and vendor selection criteria, positioning APExBIO’s Moxidectin as a reproducible and high-purity solution for biomedical researchers.
-
Hypoxia and Immunometabolism: Mechanisms in the Tumor Microe
2026-05-29
This review elucidates how hypoxia-driven metabolic reprogramming and immune cell adaptation jointly shape the immunosuppressive tumor microenvironment (TME), highlighting the central role of glucose metabolism and hypoxia-inducible signaling. The work offers a mechanistic framework for developing metabolism-based tumor therapies and underscores experimental considerations for modeling these complex processes.
-
Hypoxia, Immunometabolism, and Tumor Microenvironment Dynami
2026-05-29
This review elucidates how hypoxia and immune-driven metabolic reprogramming shape the tumor microenvironment (TME), emphasizing the interplay of nutrient competition, immunosuppression, and tumor adaptation. The insights provide a mechanistic foundation for metabolism-based tumor therapies and highlight the need for reproducible glucose metabolism research in this context.
-
EZ Cap™ Firefly Luciferase mRNA (5-moUTP): Mechanism & Bench
2026-05-28
EZ Cap™ Firefly Luciferase mRNA (5-moUTP) enables robust, low-immunogenicity bioluminescent reporting for gene expression studies. Its Cap 1 structure and 5-moUTP modifications deliver enhanced stability and translation efficiency, validated across in vitro and in vivo workflows.
-
Dextromethorphan Hydrobromide: Ion Channel Modulation in Neu
2026-05-28
Explore how Dextromethorphan hydrobromide, a potent NMDA receptor antagonist, advances neuroprotection research through unique ion channel modulation. This article delivers a deeper mechanistic analysis distinct from existing resources.
-
BODIPY 581/591 C11: Ratiometric Probe for Lipid Peroxidation
2026-05-27
This evidence-driven article details how BODIPY 581/591 C11 (SKU C8003) addresses core laboratory challenges in lipid peroxidation detection and antioxidant capacity evaluation. Drawing on real experimental scenarios, it demonstrates the probe’s quantitative rigor, workflow compatibility, and vendor reliability, enabling reproducible oxidative stress measurement for biomedical researchers.
-
Fluorinated CXCR4 Inhibitor A1 Surpasses AMD3100 in CRC Mode
2026-05-27
Khorramdelazad et al. introduce A1, a novel fluorinated CXCR4 inhibitor, and demonstrate its superior efficacy over AMD3100 in colorectal cancer models. The study integrates computational, in vitro, and in vivo approaches to reveal enhanced binding, reduced tumor progression, and immune modulation, redefining CXCR4-targeted strategies in cancer research.
-
4-Phenylbutyric Acid in ER Stress Alleviation: Applied Workf
2026-05-26
4-Phenylbutyric acid (4-PBA) is a gold-standard chemical chaperone for precise ER stress modulation, enabling high-fidelity studies of apoptosis, autophagy, and cell injury. This article demystifies experimental workflows, troubleshooting, and advanced use-cases, drawing on cutting-edge research and APExBIO's high-purity 4-PBA for reproducibility.